Activation by selegiline (Eldepryle) of REM sleep behavior disorder in parkinsonism.
Abnormal sleep-wake organization is frequently seen in idiopathic parkinsonism (PD) and other parkinsonism syndromes. A 1993 article in The Annals of Neurology first described the high rate of REM behavior disorder (RBD) in non-demented PD patients (1). In this article, we present the case reports of three non-demented PD patients who manifested RBD while on recommended doses of selegiline (Eldepryle). None of them had problems severe enough to suggest RBD while they were being treated with varying doses of other dopaminergic agents (carbidopa/L-dopa, pergolide) unaccompanied by selegiline.
Louden
M B
MB
West Virginia University School of Medicine, Morgantown, USA.
Morehead
M A
MA
Schmidt
H S
HS
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000494:pharmacology* / Q000627:therapeutic use; D012895:Sleep, REM / Q000187:drug effects*
D012642:Selegiline